CN104548096B - A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor - Google Patents
A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor Download PDFInfo
- Publication number
- CN104548096B CN104548096B CN201310468273.4A CN201310468273A CN104548096B CN 104548096 B CN104548096 B CN 104548096B CN 201310468273 A CN201310468273 A CN 201310468273A CN 104548096 B CN104548096 B CN 104548096B
- Authority
- CN
- China
- Prior art keywords
- injection
- dpp
- pharmaceutical composition
- inhibitor
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 24
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000007924 injection Substances 0.000 claims description 66
- 238000002347 injection Methods 0.000 claims description 66
- 108010019598 Liraglutide Proteins 0.000 claims description 50
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 49
- 229960002701 liraglutide Drugs 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000008215 water for injection Substances 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 20
- 238000012856 packing Methods 0.000 claims description 12
- 102100040918 Pro-glucagon Human genes 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000005374 membrane filtration Methods 0.000 claims description 10
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008103 glucose Substances 0.000 abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 33
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 20
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 19
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 11
- 238000013019 agitation Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 108010033693 saxagliptin Proteins 0.000 description 6
- 229960004937 saxagliptin Drugs 0.000 description 6
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 5
- 229940100630 metacresol Drugs 0.000 description 5
- 238000012827 research and development Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940127017 oral antidiabetic Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 229950000034 teneligliptin Drugs 0.000 description 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to field of medicine preparing technology, disclose the pharmaceutical composition and preparation method thereof of a kind of glucagon-like-peptide-1 (GLP-1) analog containing therapeutically effective amount and dipeptidyl peptidase-4 (DPP-4) inhibitor.Type-2 diabetes mellitus can effectively be prevented, slow down and be treated to the composition, it is particularly possible to the effectively concentration of control blood glucose, therefore can be used for treatment disease relevant to blood sugar concentration raising.In addition, composition of the invention can reduce the dosage of GLP-1 analog and DPP-4 inhibitor, so that their side effect be effectively reduced, the tolerance level of patient is improved.
Description
Technical field
The present invention relates to field of medicine preparing technology, and in particular to a kind of containing GLP-1 analog and DPP-4 inhibitor
Pharmaceutical composition and preparation method thereof.
Background technique
Glucagon-like-peptide-1 (GLP-1) is secreted by intestinal cell, and a parahormone of insulin secretion can be promoted.People
After eating food, enteron aisle, which is stimulated, will secrete this hormone, to reduce blood glucose.It is used in order to which drug is made in GLP-1
Clinic, scientist accurately modify the peptide chain of human body GLP-1, its half-life period so has just extended to 13 from 2 minutes
A hour, thus manufactured long-acting people GLP-1 analog, entitled " Liraglutide ".
Liraglutide is a kind of drug for treating type-2 diabetes mellitus that danish novo nordisk is developed, is GLP-1
Receptor stimulating agent, it is primary per injection day by day as a kind of subcutaneous injection formulation, good reduction blood glucose can be played and weight is made
With.Its peptide sequence is H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Le u-Glu-Gly-
Gln-Ala-Ala-Lys(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-
Val-Arg-Gly-Arg-Gly-OH.Liraglutide is in FDA approval listing in 2010, trade name promise and power (Victoza).System
Agent specification is 18mg/ml.
DPP-IV inhibitor is by inhibiting the activity of DPP-IV to promote beta Cell of islet to generate pancreas in raising GLP-1 concentration
While the element of island, Glucagon concentrations are reduced, to reduce blood glucose.Different from conventional oral hypoglycemic agent, DPP-IV inhibits
The appearance nothing of agent controls blood glucose suspected of II diabetic and provides new selection.
DPP-IV inhibitor can be individually used for treatment type II diabetes, can also combine with other conventional oral diabetes medicaments
It uses.Clinical research shows: being applied alone DPP-IV inhibitor that can reduce postprandial blood sugar and HbA1c, improves islet beta cell function, mention
Sensibility of the high body to insulin.DPP-IV inhibitor has good blood sugar decreasing effect, and adverse reaction is slight, will not
Cause weight gain and oedema, causes risk of hypoglycemia also very small.
Xi Gelieting is a kind of novel antidiabetic drug dipeptidyl peptidase-4 (DPP-4) inhibitor, and human body itself reduction can be improved
The ability of too high blood glucose level is a kind of drug for treating type-2 diabetes mellitus of United States Merck company development, acquisition FDA in 2006
Approval listing.Trade name Jie Nuowei.Its structure are as follows:
Vildagliptin is a kind of DPP-4 inhibitor researched and developed by Novartis Co., Ltd, Switzerland, in acquisition EMA approval in 2 months 2008
City, structure are as follows:
Saxagliptin is a kind of DPP-4 inhibitor of Bristol-Myers Squibb Co., U.S. research and development, obtains FDA in July, 2009
Approval listing, structure are as follows:
Li Nalieting is a kind of DPP-4 inhibitor of German Boehringer Ingelheim drugmaker research and development, obtains in May, 2011
Obtain FDA approval listing, structure are as follows:
Egelieting is a kind of DPP-4 inhibitor of Japanese Takeda Pharmaceutical Company Limited's research and development, obtains FDA approval in January, 2013
Listing, structure are as follows:
Gigue column spit of fland is a kind of DPP-4 inhibitor of LG Life Sciences, South Korea research and development, and in June, 2012 is in South Korea
City, structure are as follows:
Teneligliptin is a kind of DPP-4 inhibitor of Mitsubishi Tian Bian drugmaker research and development, and in August, 2012 is in Japan
Listing, structure are as follows:
Liraglutide is subcutaneous administrations once a day at present, although Liraglutide peptide sequence is repaired by side chain hexadecanoic acid
Decorations, extend half-life period, but since Liraglutide belongs to GLP-1, can be degraded rapidly by DPP-4 enzyme in human body, cause to need
It to inject daily once, gastrointestinal side effect etc. causes larger pain to patient.
Since DPP- VIII and DPP- Ⅸ and DPP-4 belong to same enzyme family, DPP-IV inhibitor is inhibiting DPP-IV
While, it is also possible to inhibiting effect is generated to these enzymes.
Type-2 diabetes mellitus is chronic and progressive disease, due to complicated pathologic, physiologic, is related to insulin resistance and pancreas
Island element secretes the dual endocrine defects being damaged.The treatment of type-2 diabetes mellitus typically begins with diet and exercise, then
Carry out the single current system method of oral antidiabetic.For many patients, these schemes cannot be controlled fully during long-term treatment
Blood glucose leads to the requirement of the combination therapy after diagnosis within several years.However, two or more oral antidiabetic drugs
There may be complexity and the therapeutic scheme for being difficult to follow for many patients for common prescription.
Remedies for diabetes is primarily present following problems at present: unsatisfactory curative effect, and HbA1c is increased with disease progression;It is low
Blood glucose;Patient's cardiovascular risk is high.It is when business therefore, it is necessary to find the pharmaceutical preparation of highly-safe, high curative effect and low-risk
It is anxious.
Summary of the invention
The present invention in view of the above defects of the prior art, on the one hand provides a kind of pharmaceutical composition, it includes
Glucagon-like-peptide-1 (GLP-1) analog of therapeutically effective amount, the dipeptidyl peptidase-4 (DPP-4) of therapeutically effective amount inhibit
Agent, pH adjusting agent, isotonic regulator and preservative.
In a preferred embodiment of the present invention, GLP-1 analog is Liraglutide or its salt, and DPP-4 inhibitor is selected from
One of Xi Gelieting, vildagliptin, saxagliptin, Li Nalieting, Egelieting, teneligliptin and gigue column spit of fland or its can
One of medicinal salt, more preferably Xi Gelieting, saxagliptin, Li Nalieting and Egelieting or its pharmaceutical salt,
Be further preferably one of Xi Gelieting, saxagliptin and Li Nalieting or its pharmaceutical salt, most preferably Xi Gelieting and
One of Li Nalieting or its pharmaceutical salt.
In pharmaceutical composition of the invention, pharmaceutical salt is selected from phosphate, hydrochloride, sulfate, hydrosulphuric acid salt, lemon
Lemon hydrochlorate, tartrate, acetate, benzoate, malate, maleate, fumarate, glutamate and aspartic acid
Salt.
In a preferred embodiment of the present invention, the dosage of GLP-1 is the 20%-100% that the dosage of GLP-1 is used alone,
The dosage of DPP-4 inhibitor is the 20%-100% that DPP-4 is used alone and inhibits agent dose;The dosage of GLP-1 is more preferably 0.1-
10mg/ml is further preferably 0.1-5mg/ml, most preferably 0.2-3.6mg/ml;The dosage of DPP-4 inhibitor is more preferably
0.1mg-100mg/ml is further preferably 0.25-50mg/ml, most preferably 0.25-20mg/ml.
In pharmaceutical composition of the invention, pH adjusting agent is selected from hydrochloric acid, acetate buffer solution, phosphate buffer, citric acid
Buffer, sodium hydroxide, sodium carbonate, sodium bicarbonate and disodium hydrogen phosphate are preferably selected from disodium hydrogen phosphate, sodium carbonate and hydroxide
Sodium.
In pharmaceutical composition of the invention, isotonic regulator is selected from propylene glycol, mannitol, sodium chloride, glucose, fruit
Sugar, magnesium chloride, polyethylene glycol, glycerol, lactose, galactolipin and xylitol, are preferably selected from mannitol and propylene glycol.
In pharmaceutical composition of the invention, preservative be selected from anesin, benzoic acid and its salt, sorbic acid and its
One of salt, metacresol, phenol or combination, preferably one of anesin, metacresol, phenol or combination, it is more excellent
It is selected as anesin.
In a preferred embodiment of the present invention, the dosage of preservative is 1-10mg/ml, and the dosage of isotonic regulator is 5-
20mg/ml, pH range are 7.0-9.0, preferably 7.5-8.5, more preferably 7.8-8.4.
In a preferred embodiment of the present invention, pharmaceutical composition of the invention is injection dosage form, dosage form
Preferably peace cuts open bottle or prefilled injection pen.
Another aspect of the present invention additionally provides the method for preparing pharmaceutical composition of the present invention, includes the following steps:
1, the preservative and isotonic regulator for weighing recipe quantity, are added in material-compound tank;
2, appropriate water for injection is added to be completely dissolved;
3, it takes appropriate water for injection to be completely dissolved the GLP-1 analog of recipe quantity and DPP-4 inhibitor, is added to above-mentioned
In material-compound tank;
4, with water for injection constant volume;
5, it adjusts and arrives target ph;
6, using 0.22 μm of membrane filtration degerming, injection is made in packing.
In a preferred embodiment of the present invention, the dosage of composition is prepared into 1 time a day or at a suitable time
The suitable dose at interval exists, such as 3 days 2 times or 2 days 1 time.
In a preferred embodiment of the present invention, the preparation of composite injection aseptically carries out.
Compared with GLP-1 analog or DPP-4 inhibitor is used alone, it is of the invention comprising GLP-1 analog and
The pharmaceutical composition of DPP-4 inhibitor can significantly improve blood glucose.Inhibit for GLP-1 analog or DPP-4 is used alone
Agent, usual dosage is higher, enteron aisle side effect is larger, patient's poor resistance, all patients can not be made to reach control blood glucose purpose.
And with the sustainable development of diabetes, diabetic will appear many complication, such as arterial sclerosis, pedopathy (foot
Gangrene, amputation), nephrosis (renal failure, uremia), eye disease (smudgy, blindness), encephalopathy (cerebrovascular disease), heart
Disease, skin disease, venereal disease etc..Compared with independent medication, pharmaceutical composition of the invention can effectively control blood sugar concentration, make blood glucose
Level drops to 6% level or more.It follows that II type sugar can effectively be prevented, slow down and be treated to pharmaceutical composition of the invention
Urine disease, it is particularly possible to the effectively concentration of control blood glucose, therefore can be used for treatment disease relevant to blood sugar concentration raising.Together
When, since the GLP-1 activity of GLP-1 analog is utilized in pharmaceutical composition of the invention, patient can also be effectively reduced
Weight.
In addition, composition of the invention can reduce the dosage of GLP-1 analog and DPP-4 inhibitor, to have
Effect reduces their side effect, improves the tolerance level of patient.
Specific embodiment
Below by embodiment, the present invention is described in further detail, it is intended to limit this for illustrating rather than
Invention.It should be pointed out that those skilled in the art, it without departing from the principle of the present invention, can also be to this hair
Bright some improvement and modification can also be carried out, these improvement and modification are similarly fallen under the scope of the present invention.
Embodiment 1: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 300mg anesin, 1500mg are weighed
Mannitol is added in material-compound tank after 150mL water for injection stirring and dissolving is added;Weigh 30mg Liraglutide, 3000mg phosphoric acid
Xi Gelieting (to the west of Ge Lieting calculate) is added the dissolution of 50mL water for injection, is added in above-mentioned Agitation Tank solution, stirring and dissolving
It is clarified to solution, 0.1N sodium hydroxide is added, the pH value for adjusting solution is 8.0, remaining injection water constant volume is supplemented, using 0.22
μm membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 2: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 3000mg anesin is weighed,
2500mg propylene glycol is added in material-compound tank after 150mL water for injection stirring and dissolving is added;1080mg Liraglutide is weighed,
3000mg phosphoric acid Xi Gelieting (to the west of Ge Lieting calculate) is added the dissolution of 50mL water for injection, is added to above-mentioned Agitation Tank solution
In, stirring and dissolving to solution is clarified, and 0.1N sodium hydroxide is added, and the pH value for adjusting solution is 8.4, and it is fixed to supplement remaining injection water
Hold, using 0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 3: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 3000mg anesin is weighed,
2500mg propylene glycol is added in material-compound tank after 150mL water for injection stirring and dissolving is added;600mg Liraglutide is weighed,
600mg phosphoric acid Xi Gelieting (to the west of Ge Lieting calculate) is added the dissolution of 50mL water for injection, is added to above-mentioned Agitation Tank solution
In, stirring and dissolving to solution is clarified, and 0.1N sodium hydroxide is added, and the pH value for adjusting solution is 8.4, and it is fixed to supplement remaining injection water
Hold, using 0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 4: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 3000mg anesin is weighed,
5000mg propylene glycol is added in material-compound tank after 150mL water for injection stirring and dissolving is added;600mg Liraglutide is weighed,
600mg phosphoric acid Xi Gelieting (to the west of Ge Lieting calculate) is added the dissolution of 50mL water for injection, is added to above-mentioned Agitation Tank solution
In, stirring and dissolving to solution is clarified, and appropriate 10% aqueous sodium carbonate is added, and the pH value for adjusting solution is 7.6, supplements remaining note
Jetting amount constant volume, using 0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 5: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 1500mg phenol, 4000mg sweet dew are weighed
Alcohol is added in material-compound tank after 150mL water for injection stirring and dissolving is added;Weigh 600mg Liraglutide, the western lattice of 600mg phosphoric acid
Spit of fland (to the west of Ge Lieting calculate) is arranged, the dissolution of 50mL water for injection is added, is added in above-mentioned Agitation Tank solution, stirring and dissolving is to molten
Liquid clarification, is added appropriate 10% aqueous sodium carbonate, and the pH value for adjusting solution is 7.6, supplements remaining injection water constant volume, uses
0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 6: the preparation of Liraglutide and Li Nalieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 2000mg metacresol is weighed, 6000mg is sweet
Reveal alcohol, after 150mL water for injection stirring and dissolving is added, is added in material-compound tank;Weigh 300mg Liraglutide, 600mg Li Nalie
Spit of fland (is calculated) with Li Nalieting, and the dissolution of 50mL water for injection is added, is added in above-mentioned Agitation Tank solution, stirring and dissolving to solution
Appropriate 10% aqueous sodium carbonate is added in clarification, and the pH value for adjusting solution is 8.2, supplements remaining injection water constant volume, uses
0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 7: the preparation of Liraglutide and saxagliptin injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 2000mg metacresol is weighed, 6000mg is sweet
Reveal alcohol, after 150mL water for injection stirring and dissolving is added, is added in material-compound tank;Weigh 300mg Liraglutide, 600mg Sha Gelie
Spit of fland (is calculated) with saxagliptin, and the dissolution of 50mL water for injection is added, is added in above-mentioned Agitation Tank solution, stirring and dissolving to solution
Appropriate 10% aqueous sodium carbonate is added in clarification, and the pH value for adjusting solution is 8.0, supplements remaining injection water constant volume, uses
0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 8: the preparation of Liraglutide and Egelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 2000mg metacresol is weighed, 6000mg is sweet
Reveal alcohol, after 150mL water for injection stirring and dissolving is added, is added in material-compound tank;Weigh 300mg Liraglutide, 600mg benzoic acid
Egelieting (is calculated) with Egelieting, and the dissolution of 50mL water for injection is added, is added in above-mentioned Agitation Tank solution, stirring and dissolving
It is clarified to solution, appropriate 10% aqueous sodium carbonate is added, the pH value for adjusting solution is 8.4, remaining injection water constant volume is supplemented,
Using 0.22 μm of membrane filtration degerming;Packing is into injection pen, every 3ml, and totally 100.
Embodiment 9: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 200g anesin is weighed, 600g is sweet
Reveal alcohol, after 15L water for injection stirring and dissolving is added, is added in material-compound tank;Weigh 30g Liraglutide, 45g phosphoric acid Xi Gelieting
(to the west of Ge Lieting calculate) is added the dissolution of 5L water for injection, is added in above-mentioned Agitation Tank solution, stirring and dissolving is clear to solution
Clearly, appropriate 0.1N sodium hydrate aqueous solution is added, the pH value for adjusting solution is 8.4, supplements remaining injection water constant volume, crosses and filter out
Bacterium;Packing is into injection pen, every 3ml, and totally 10000.
Embodiment 10: the preparation of Liraglutide and Xi Gelieting injection
1, formula of liquid is injected
2, preparation process
In ten thousand grades of toilets and on clean indoor hundred-grade super-clean workbench, 300g anesin is weighed, 450g is sweet
Reveal alcohol, after 15L water for injection stirring and dissolving is added, is added in material-compound tank;Weigh 75g Liraglutide, 45g phosphoric acid Xi Gelieting
(to the west of Ge Lieting calculate) is added the dissolution of 5L water for injection, is added in above-mentioned Agitation Tank solution, stirring and dissolving is clear to solution
Clearly, appropriate 0.1N sodium hydrate aqueous solution is added, the pH value for adjusting solution is 8.4, supplements remaining injection water constant volume, crosses and filter out
Bacterium;Packing is into injection pen, every 3ml, and totally 10000.
Embodiment 11: Detection of Stability
Liraglutide and DPP-4 prepared by 1-10 of the embodiment of the present invention inhibits remover liquid injection respectively in strong light hot conditions
Lower 40 DEG C are placed 5 days and 10 days, then separately sampled, detect the variation of its purity, solution clarity and bacterial growth situation, detection
The results are shown in Table 1.
Table 1 is provided by the invention to penetrate liquid Detection of Stability
As shown in Table 1, the Li Lalu that the embodiment of the present invention 1, embodiment 3, embodiment 6, embodiment 7 and embodiment 10 provide
Peptide inhibits Liraglutide purity decrease speed in remover liquid injection most slow with DPP-4.
The Liraglutide and DPP-4 for taking the embodiment of the present invention 1, embodiment 6 and embodiment 10 to provide inhibit remover liquid injection to exist
2-8 DEG C of temperature under 60% holding conditions of relative humidity, further detects the long-term steady of Liraglutide injection provided by the invention
Qualitative, solution clarity variation and bacterial growth situation, testing result are as shown in table 2.
2 Liraglutide of table and DPP-4 inhibit remover liquid injection study on the stability result
As shown in Table 2, Liraglutide and DPP-4 inhibitor that the embodiment of the present invention 1, embodiment 6 and embodiment 10 provide
Injection is qualified in content, clarity and bacterial growth situation after storage 12 months, and quality is stablized.
The testing result for the Liraglutide injection that other embodiments of the invention provide is similarly.
Comprehensive Tables 1 and 2 is it is found that Liraglutide injection provided by the invention is with good stability, buffer pH tune
Section system maintains the pH of Liraglutide injection provided by the invention between 6~7.5, and it is most suitable to guarantee that Liraglutide is stored in
Under the conditions of pH;And the use of bacteriostatic agent grow bacterium can not, the degradation so as to avoid bacterium to Liraglutide;Show pH tune
Section agent and the use of bacteriostatic agent ensure that the stability of Liraglutide.
Embodiment 12: hypoglycemic effect detection
The Liraglutide and Xi Gelieting injection for taking the embodiment of the present invention 10 to provide, carry out hypoglycemic effect detection, take city
The Liraglutide injection and Jie Nuowei (phosphoric acid Xi Gelieting piece) sold are as control.
Male and healthy SD rat 50, weight 200g~250g are taken, cleaning grade.It randomly selects and wherein 10 is only used as normally
Group, feeding basal feed, with 1.5mL water for injection stomach-filling.After remaining rat adaptable fed 5d, that is, start feeding feeding high in fat
Material cooperates normal diet, and after 7 days, overnight fast, normal group of next day replaces streptozotocin to be injected intraperitoneally with physiological saline,
It is remaining (to be prepared with the sterile citrate buffer solution of 0.1mol/L, pH value 4.5) with streptozotocin with 50mg/kg intraperitoneal injection,
Tail is cut after 72 hours surveys blood glucose, the modeling Success Flag using fasting blood-glucose > 11.1mmol/L as diabetes rat.
After modeling success, it is divided into normal group A;Model control group B;Phosphoric acid Xi Gelieting piece is administered orally daily morning and evening twice
Administration group C, each 2mgKg-1;Liraglutide and Xi Gelieting injection the nape of the neck subcutaneous administration administration group D once a week, often
Secondary 0.4mgKg-1;Liraglutide injection the nape of the neck subcutaneous administration administration group E, each 0.6mgKg once a day-1.Administration
The 0th week afterwards, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks collection tail veins detected blood glucose value with blood glucose meter, and each data of this experiment are adopted
Processing analysis is carried out with SPSS16.0 software, each group compares to be examined using t, and testing result is as shown in table 3.
3 experimental rat blood glucose value (mmol/L) of table
Group | Number of animals | Before injection | Injection 1 week | Injection 2 weeks | Injection 3 weeks | Injection 4 weeks | Injection 5 weeks | Injection 6 weeks |
A group | 10 | 5.1±1.0 | 5.2±1.1 | 5.3±1.5 | 5.3±1.3 | 5.5±2.0 | 5.6±2.5 | 5.4±1.4 |
B group | 10 | 15.8±3.1 | 18.0±3.5 | 20.3±4.0 | 23.7±3.8 | 24.6±4.4 | 26.0±2.5 | 28.7±3.3 |
C group | 10 | 17.3±2.2 | 13.8±1.3 | 12.2±1.2 | 9.8±2.0 | 8.7±1.4 | 7.6±1.7 | 6.0±2.1 |
D group | 10 | 17.5±1.5 | 9.6±2.0 | 7.9±2.5 | 6.8±1.1 | 6.0±1.0 | 5.2±1.5 | 4.8±1.0 |
E group | 10 | 17.4±2.0 | 12.7±1.0 | 11.0±1.0 | 8.4±2.4 | 7.0±1.1 | 6.0±1.6 | 5.6±1.3 |
As shown in Table 3, compared with A group, there is significant difference in B group P < 0.01;Compared with B group, C, D, E group P < 0.01 have
Significant difference;Compared with C group, D, E group P > 0.05, there was no significant difference, and total hypoglycemic effect is suitable.But it can from upper table
Out, Liraglutide and Xi Gelieting injection and Liraglutide injection hypoglycemic effect will be slightly faster than oral phosphoric acid Xi Gelieting.
As can also be seen from Table 3, although Liraglutide provided by the invention and Xi Gelieting injection and commercially available existing drop
Sugared injection is compared, and hypoglycemic effect is suitable, all has significant hypoglycemic effect.But Liraglutide provided by the invention and western lattice
Column spit of fland injection hypoglycemic speed is slightly faster than commercially available oral phosphoric acid Xi Gelieting piece and Li Lula peptide injection.
The Liraglutide and DPP-4 that other embodiments of the invention provide inhibit the testing result and embodiment 10 of remover liquid injection
Result it is similar.
Claims (7)
1. a kind of pharmaceutical composition, which is characterized in that it includes the glucagon-like-peptide-1 of therapeutically effective amount (GLP-1) is similar
Dipeptidyl peptidase-4 (DPP-4) inhibitor, pH adjusting agent, isotonic regulator and the preservative of object, therapeutically effective amount;The GLP-
1 analog is Liraglutide or its salt;The DPP-4 inhibitor is Xi Gelieting or its pharmaceutical salt;The agent of the GLP-1
Amount is 2.5mg/ml, and the dosage of the DPP-4 inhibitor is 1.5mg/ml;The isotonic regulator is 15mg/ml mannitol;
The preservative is the anesin of 10mg/ml;The pH adjusting agent is sodium hydroxide, and the composition pH is 8.4.
2. pharmaceutical composition according to claim 1, which is characterized in that wherein pharmaceutical salt is selected from phosphate, hydrochloric acid
Salt, sulfate, hydrosulphuric acid salt, citrate, tartrate, acetate, benzoate, malate, maleate, fumaric acid
Salt, glutamate, aspartate.
3. pharmaceutical composition according to claim 1, which is characterized in that it is injection dosage form, and dosage form is that peace is cutd open
Bottle or prefilled injection pen.
4. the method for preparing pharmaceutical composition of any of claims 1-3 includes the following steps: that (1) weighs prescription
The preservative and isotonic regulator of amount, are added in material-compound tank;(2) appropriate water for injection is added to be completely dissolved;(3) appropriate note is taken
It penetrates and is completely dissolved the GLP-1 analog of recipe quantity and DPP-4 inhibitor with water, be added in above-mentioned material-compound tank;(4) with injection
With water constant volume;(5) it adjusts and arrives target ph;(6) 0.22 μm of membrane filtration degerming is used, injection is made in packing.
5. the preparation method of pharmaceutical composition according to claim 4, wherein the dosage of the composition be 1 time a day or
The suitable dose of person at appropriate time intervals exists.
6. the preparation method of pharmaceutical composition according to claim 5, which is characterized in that the time interval is 3 days 2 times
Or 2 days 1 time.
7. the preparation method of pharmaceutical composition according to claim 4, wherein the preparation of composite injection is sterile
Under the conditions of carry out.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310468273.4A CN104548096B (en) | 2013-10-09 | 2013-10-09 | A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310468273.4A CN104548096B (en) | 2013-10-09 | 2013-10-09 | A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104548096A CN104548096A (en) | 2015-04-29 |
CN104548096B true CN104548096B (en) | 2019-09-10 |
Family
ID=53065862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310468273.4A Expired - Fee Related CN104548096B (en) | 2013-10-09 | 2013-10-09 | A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104548096B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107249620B (en) * | 2015-05-13 | 2018-06-26 | 杭州九源基因工程有限公司 | A kind of pharmaceutical preparation comprising GLP-1 analogs and preparation method thereof |
CN106310237A (en) * | 2016-08-22 | 2017-01-11 | 卢连伟 | Compound hypoglycemic preparation containing liraglutide and preparation method thereof |
CN108096227A (en) * | 2018-01-25 | 2018-06-01 | 河北科技大学 | The molten film preparation in Egelieting oral cavity |
CN114350547B (en) * | 2021-12-17 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101357924A (en) * | 2007-08-01 | 2009-02-04 | 山东轩竹医药科技有限公司 | Dipeptidase-IV inhibitor compounds |
CN101495502A (en) * | 2006-05-26 | 2009-07-29 | 百时美施贵宝公司 | N-terminally modified GLP-1 receptor modulators |
CN101595109A (en) * | 2006-11-20 | 2009-12-02 | 百时美施贵宝公司 | As 7 of inhibitors of dipeptidyl IV, 8-dihydro-1,6-naphthyridine-5 (6H)-ketone and related bicyclic compounds and method |
CN102946875A (en) * | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | Combination therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130172244A1 (en) * | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
-
2013
- 2013-10-09 CN CN201310468273.4A patent/CN104548096B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101495502A (en) * | 2006-05-26 | 2009-07-29 | 百时美施贵宝公司 | N-terminally modified GLP-1 receptor modulators |
CN101595109A (en) * | 2006-11-20 | 2009-12-02 | 百时美施贵宝公司 | As 7 of inhibitors of dipeptidyl IV, 8-dihydro-1,6-naphthyridine-5 (6H)-ketone and related bicyclic compounds and method |
CN101357924A (en) * | 2007-08-01 | 2009-02-04 | 山东轩竹医药科技有限公司 | Dipeptidase-IV inhibitor compounds |
CN102946875A (en) * | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | Combination therapy |
Also Published As
Publication number | Publication date |
---|---|
CN104548096A (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6852690B1 (en) | Method and composition for enhanced parenteral nutrition | |
EP0851763B1 (en) | Method and composition for enhanced parenteral nutrition | |
CN102363633B (en) | Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof | |
CN101095942B (en) | Formulation of the Exendin injection medicine containing stabilizing agent | |
KR102093872B1 (en) | Injection Composition For Fat Reduction and method of manufacturing the same | |
CN107249620B (en) | A kind of pharmaceutical preparation comprising GLP-1 analogs and preparation method thereof | |
CN101883609A (en) | Injectable rapid-acting insulin composition | |
TW201100093A (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
CN104548096B (en) | A kind of pharmaceutical composition and preparation method thereof containing GLP-1 analog and DPP-4 inhibitor | |
Pintor et al. | Clonidine accelerates growth in children with impaired growth hormone secretion | |
EP3527195B1 (en) | Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof | |
KR20200131812A (en) | Compositions and methods for treating metabolic diseases | |
JP2024038042A (en) | GLP-1 compositions for obesity treatment and weight management | |
JP6328552B2 (en) | Honey composition with L-alanyl-L-glutamine | |
WO2006085100A1 (en) | Treatment of very low birthweight (vlbw) infants by increasing blood insulin levels | |
CN113956334B (en) | Application of brown adipocyte secretory peptide and derivative thereof in prevention and treatment of obesity | |
AU2018329496A1 (en) | Sublingual epinephrine tablets | |
JPWO2017018500A1 (en) | GLP-1 secretion promoter | |
Atabek et al. | Some effect of metformin on insulin resistance in an infant with leprechaunism | |
CN104402990A (en) | Polypeptide for treating diabetes | |
WO2014187302A1 (en) | Dulaglutide injection and preparation method thereof | |
CN103566354A (en) | Pharmaceutical composition containing derivatives of GLP-1 analogue or medicinal salts thereof | |
KR20200103029A (en) | Treatment of exercise-induced hypoglycemia in type 1 diabetes and type 2 diabetes with insulin | |
McElduff et al. | Metastatic medullary carcinoma of the thyroid complicated by Cushing's syndrome | |
CN101184509A (en) | Agent for improvement of insulin resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190910 Termination date: 20201009 |
|
CF01 | Termination of patent right due to non-payment of annual fee |